Drug Profile
Research programme: dilated cardiomyopathy therapeutics - Adrenergics
Latest Information Update: 28 Jul 2019
Price :
$50
*
At a glance
- Originator Adrenergics
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dilated cardiomyopathy
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for research development in Dilated cardiomyopathy(Treatment-resistant) in USA
- 15 Jun 2015 Early research in Dilated cardiomyopathy (Treatment-resistant) in USA (unspecified route)